Aims: An increased kidney cancer risk was found in hypertensive patients, who frequently exhibit hyperaldosteronism, known to contribute to kidney injury, with oxidative stress playing an important role. The capacity of kidney cells to up-regulate transcription factor nuclear factor-erythroid-2-related factor 2 (Nrf2), a key regulator of the cellular antioxidative defense, as a prevention of aldosterone-induced oxidative damage was investigated both in vitro and in vivo. Results: Aldosterone activated Nrf2 and increased the expression of enzymes involved in glutathione (GSH) synthesis and detoxification. This activation depended on the mineralocorticoid receptor (MR) and oxidative stress. In vitro, Nrf2 activation, GSH amounts, and target gene levels decreased after 24 h, while oxidant levels remained high. Nrf2 activation could not protect cells against oxidative DNA damage, as aldosterone-induced double-strand breaks and 7,8-dihydro-8-oxo-guanine (8-oxodG) lesions steadily rose. The Nrf2 activator sulforaphane enhanced the Nrf2 response both in vitro and in vivo, thereby preventing aldosterone-induced DNA damage. In vivo, Nrf2 activation further had beneficial effects on the aldosterone-caused blood pressure increase and loss of kidney function. Innovation: This is the first study showing the activation of Nrf2 by aldosterone. Moreover, the results identify sulforaphane as a substance that is capable of preventing aldosterone-induced damage both in vivo and in vitro. Conclusion: Aldosterone-induced Nrf2 adaptive response cannot neutralize oxidative actions of chronically increased aldosterone, which, therefore could be causally involved in the increased cancer incidence of hypertensive individuals. Enhancing the cellular antioxidative defense with sulforaphane might exhibit beneficial effects. Antioxid. Redox Signal. 21, 2126–2142.
Get full access to this article
View all access options for this article.
References
1.
AokiY, SatoH, NishimuraN, TakahashiS, ItohK, and YamamotoM. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol, 173: 154–160, 2001.
2.
BonnerWM, RedonCE, DickeyJS, NakamuraAJ, SedelnikovaOA, SolierS, and PommierY. GammaH2AX and cancer. Nat Rev Cancer, 8: 957–967, 2008.
3.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72: 248–254, 1976.
4.
BurdetteD, OlivarezM, and WarisG. Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. J Gen Virol, 91: 681–690, 2010.
5.
CalhounDA, JonesD, TextorS, GoffDC, MurphyTP, TotoRD, WhiteA, CushmanWC, WhiteW, SicaD, et al.Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 117: e510–e526, 2008.
6.
ChenTM, LiJ, LiuL, FanL, LiXY, WangYT, AbrahamNG, and CaoJ. Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int J Mol Sci, 14: 2684–2706, 2013.
7.
ChengKC, CahillDS, KasaiH, NishimuraS, and LoebLA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—T and A—C substitutions. J Biol Chem, 267: 166–172, 1992.
8.
CookeMS, OlinskiR, and EvansMD. Does measurement of oxidative damage to DNA have clinical significance?. Clin Chim Acta, 365: 30–49, 2006.
9.
CrowJP. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide, 1: 145–157, 1997.
10.
de ZeeuwD, AkizawaT, AgarwalR, AudhyaP, BakrisGL, ChinM, KrauthM, Lambers HeerspinkHJ, MeyerCJ, McMurrayJJ, et al.Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol, 37: 212–222, 2013.
11.
DhakshinamoorthyS and PorterAG. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J Biol Chem, 279: 20096–20107, 2004.
12.
FriisS, SorensenHT, MellemkjaerL, McLaughlinJK, NielsenGL, BlotWJ, and OlsenJH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer, 92: 2462–2470, 2001.
13.
FunderJ and NewMI. Low renin hypertension (LRH): shades of John Laragh. Trends Endocrinol Metab, 19: 83, 2008.
14.
GaoL and MannGE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res, 82: 9–20, 2009.
15.
GeggME, BeltranB, Salas-PinoS, BolanosJP, ClarkJB, MoncadaS, and HealesSJ. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?. J Neurochem, 86: 228–237, 2003.
16.
GekleM, FreudingerR, MildenbergerS, and SilbernaglS. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol Renal Physiol, 282: F669–F679, 2002.
17.
GiusD and SpitzDR. Redox signaling in cancer biology. Antioxid Redox Signal, 8: 1249–1252, 2006.
18.
Gomez-GuzmanM, JimenezR, SanchezM, ZarzueloMJ, GalindoP, QuintelaAM, Lopez-SepulvedaR, RomeroM, TamargoJ, VargasF, et al.Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med, 52: 70–79, 2012.
19.
GriendlingKK, SorescuD, and Ushio-FukaiM. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 86: 494–501, 2000.
20.
GrossmanE, MesserliFH, BoykoV, and GoldbourtU. Is there an association between hypertension and cancer mortality?. Am J Med, 112: 479–486, 2002.
21.
HabibSL, DanialE, NathS, SchneiderJ, JenkinsonCP, DuggiralaR, AbboudHE, and ThameemF. Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis. Cancer Biol Ther, 7: 23–27, 2008.
22.
HarveyBJ and HigginsM. Nongenomic effects of aldosterone on Ca2+ in M-1 cortical collecting duct cells. Kidney Int, 57: 1395–1403, 2000.
23.
HayashiH, KobaraM, AbeM, TanakaN, GoudaE, TobaH, YamadaH, TatsumiT, NakataT, and MatsubaraH. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res, 31: 363–375, 2008.
24.
HuangHC, NguyenT, and PickettCB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci U S A, 97: 12475–12480, 2000.
25.
JacksonSP and BartekJ. The DNA-damage response in human biology and disease. Nature, 461: 1071–1078, 2009.
26.
JeggoPA and LobrichM. DNA double-strand breaks: their cellular and clinical impact?. Oncogene, 26: 7717–7719, 2007.
27.
KangKW, ChoiSH, and KimSG. Peroxynitrite activates NF-E2-related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction. Nitric Oxide, 7: 244–253, 2002.
28.
KimHJ and VaziriND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol, 298: F662–F671, 2010.
29.
KrugerNJ. The Bradford method for protein quantitation. Methods Mol Biol, 32: 9–15, 1994.
30.
LamprechtMR, SabatiniDM, and CarpenterAE. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques, 42: 71–75, 2007.
31.
LansH and HoeijmakersJH. Genome stability, progressive kidney failure and aging. Nat Genet, 44: 836–838, 2012.
32.
LauA, VilleneuveNF, SunZ, WongPK, and ZhangDD. Dual roles of Nrf2 in cancer. Pharmacol Res, 58: 262–270, 2008.
33.
LeckieC, ChapmanKE, EdwardsCR, and SecklJR. LLC-PK1 cells model 11 beta-hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors. Endocrinology, 136: 5561–5569, 1995.
34.
LoselRM, FeuringM, FalkensteinE, and WehlingM. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids, 67: 493–498, 2002.
35.
MackenzieGG, ZagoMP, KeenCL, and OteizaPI. Low intracellular zinc impairs the translocation of activated NF-kappa B to the nuclei in human neuroblastoma IMR-32 cells. J Biol Chem, 277: 34610–34617, 2002.
36.
McKinnonPJ and CaldecottKW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet, 8: 37–55, 2007.
37.
NaganumaT, NakayamaT, SatoN, FuZ, SomaM, YamaguchiM, ShimodairaM, AoiN, and UsamiR. Haplotype-based case-control study on human apurinic/apyrimidinic endonuclease 1/redox effector factor-1 gene and essential hypertension. Am J Hypertens, 23: 186–191, 2010.
38.
OsburnWO and KenslerTW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res, 659: 31–39, 2008.
39.
ParaviciniTM and TouyzRM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care, 31Suppl 2: S170–S180, 2008.
40.
PergolaPE, RaskinP, TotoRD, MeyerCJ, HuffJW, GrossmanEB, KrauthM, RuizS, AudhyaP, Christ-SchmidtH, et al.Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med, 365: 327–336, 2011.
41.
QueisserN, AmannK, HeyV, HabibSL, and SchuppN. Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic Biol Med, 54: 17–25, 2013.
42.
QueisserN, FazeliG, and SchuppN. Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biol Chem, 391: 1265–1279, 2010.
43.
QueisserN, OteizaPI, StopperH, OliRG, and SchuppN. Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells. Mol Carcinog, 50: 123–135, 2011.
44.
QueisserN, SchuppN, StopperH, SchinzelR, and OteizaPI. Aldosterone increases kidney tubule cell oxidants through calcium-mediated activation of NADPH oxidase and nitric oxide synthase. Free Radic Biol Med, 51: 1996–2006, 2011.
45.
RasbandWS. Image J Software Program. U.S. National Institute of Health, Bethesda, MD, 1997–2008.
46.
RogersonFM, YaoYZ, ElsassRE, DimopoulosN, SmithBJ, and FullerPJ. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Mol Endocrinol, 21: 817–828, 2007.
47.
RossiGP, BerniniG, CaliumiC, DesideriG, FabrisB, FerriC, GanzaroliC, GiacchettiG, LetiziaC, MaccarioM, et al.A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol, 48: 2293–2300, 2006.
48.
SchuppN, KolkhofP, QueisserN, GartnerS, SchmidU, KretschmerA, HartmannE, OliRG, SchaferS, and StopperH. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J, 25: 968–978, 2011.
49.
SchuppN, QueisserN, WolfM, KolkhofP, BarfackerL, SchaferS, HeidlandA, and StopperH. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res, 42: 458–465, 2010.
50.
SchuppN, SchmidU, RutkowskiP, LaknerU, KanaseN, HeidlandA, and StopperH. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol, 292: F1427–F1434, 2007.
51.
ShihAY, JohnsonDA, WongG, KraftAD, JiangL, ErbH, JohnsonJA, and MurphyTH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci, 23: 3394–3406, 2003.
52.
SkottO, UhrenholtTR, SchjerningJ, HansenPB, RasmussenLE, and JensenBL. Rapid actions of aldosterone in vascular health and disease—friend or foe?. Pharmacol Ther, 111: 495–507, 2006.
53.
StenvinkelP and LarssonTE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis, 62: 339–351, 2013.
54.
SurhYJ, KunduJK, LiMH, NaHK, and ChaYN. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress. Arch Pharm Res, 32: 1163–1176, 2009.
55.
SurhYJ, KunduJK, and NaHK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med, 74: 1526–1539, 2008.
56.
SurhYJ and NaHK. NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr, 2: 313–317, 2008.
57.
TalalayP, FaheyJW, HoltzclawWD, PresteraT, and ZhangY. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett, 82: 173–179, 1995.
58.
WeberKT. Aldosterone in congestive heart failure. N Engl J Med, 345: 1689–1697, 2001.
59.
WesthoffJH, HilgersKF, SteinbachMP, HartnerA, KlankeB, AmannK, and MelkA. Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension, 52: 123–129, 2008.
60.
YisireyiliM, ShimizuH, SaitoS, EnomotoA, NishijimaF, and NiwaT. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci, 92: 1180–1185, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
